Compounds > 3,4,5-trihydroxybenzohydroxamic acid
Page last updated: 2024-11-07

3,4,5-trihydroxybenzohydroxamic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID100590
CHEMBL ID174366
SCHEMBL ID131601
SCHEMBL ID13924992
SCHEMBL ID18731572
MeSH IDM0110226

Synonyms (20)

Synonym
vf 122
3,4,5,n-tetrahydroxy-benzamide
3,4,5-trihydroxybenzenecarbohydroxamic acid
3,5-trihydroxyphenylhydroxamic acid
3,5-trihydroxybenzohydroxamic acid
benzamide,3,4,5-tetrahydroxy-
69839-82-3
nsc-324362
nsc324362
vf-122
CHEMBL174366 ,
bdbm50056924
n,3,4,5-tetrahydroxybenzamide
3,4,5-trihydroxybenzohydroxamic acid
nsc 324362
benzamide, n,3,4,5-tetrahydroxy-
SCHEMBL131601
SCHEMBL13924992
DTXSID30220133
SCHEMBL18731572
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Integrase Human immunodeficiency virus 2IC50 (µMol)1.60000.50001.43752.5000AID91587; AID91589
Integrase Human immunodeficiency virus 1IC50 (µMol)1.60000.00051.544310.0000AID93700; AID93702; AID93705; AID93707
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (19)

Assay IDTitleYearJournalArticle
AID1124484Antitumor activity against mouse L1210 cells allografted in C6D2F1 mouse at 200 mg/kg, ip for 8 days starting from day 1 of challenge relative to control1979Journal of medicinal chemistry, May, Volume: 22, Issue:5
Synthesis of hydroxy- and amino-substituted benzohydroxamic acids: inhibition of ribonucleotide reductase and antitumor activity.
AID91561Percentage inhibition of compound against 3'-processing of HIV-1 integrase at 100 ug/mL1997Journal of medicinal chemistry, Mar-14, Volume: 40, Issue:6
Depsides and depsidones as inhibitors of HIV-1 integrase: discovery of novel inhibitors through 3D database searching.
AID1124480Antitumor activity against mouse L1210 cells allografted in C6D2F1 mouse at 139 mg/kg, ip bid at interval of 1 hr between each dosing for 8 days starting from day 1 of challenge relative to control1979Journal of medicinal chemistry, May, Volume: 22, Issue:5
Synthesis of hydroxy- and amino-substituted benzohydroxamic acids: inhibition of ribonucleotide reductase and antitumor activity.
AID1124476Inhibition of ribonucleotide reductase purified from rat Novikoff hepatoma assessed as inhibition of [3H]CDP to [3H]dCDP conversion after 40 mins1979Journal of medicinal chemistry, May, Volume: 22, Issue:5
Synthesis of hydroxy- and amino-substituted benzohydroxamic acids: inhibition of ribonucleotide reductase and antitumor activity.
AID1124491Antitumor activity against mouse L1210 cells allografted in C6D2F1 mouse at 100 mg/kg, ip for 8 days starting from day 1 of challenge relative to control1979Journal of medicinal chemistry, May, Volume: 22, Issue:5
Synthesis of hydroxy- and amino-substituted benzohydroxamic acids: inhibition of ribonucleotide reductase and antitumor activity.
AID91562Percentage inhibition against strand transfer of HIV-1 integrase at 100 ug/mL1997Journal of medicinal chemistry, Mar-14, Volume: 40, Issue:6
Depsides and depsidones as inhibitors of HIV-1 integrase: discovery of novel inhibitors through 3D database searching.
AID91587Inhibitory concentration of compound against 3' processing of HIV-2 integrase1997Journal of medicinal chemistry, Mar-14, Volume: 40, Issue:6
Depsides and depsidones as inhibitors of HIV-1 integrase: discovery of novel inhibitors through 3D database searching.
AID1124493Antitumor activity against mouse L1210 cells allografted in C6D2F1 mouse at 800 mg/kg, ip for 8 days starting from day 1 of challenge relative to control1979Journal of medicinal chemistry, May, Volume: 22, Issue:5
Synthesis of hydroxy- and amino-substituted benzohydroxamic acids: inhibition of ribonucleotide reductase and antitumor activity.
AID1124479Antitumor activity against ip dosed mouse L1210 cells allografted in C6D2F1 mouse assessed as dose to achieve maximum life span administered for 8 days starting from day 1 of challenge1979Journal of medicinal chemistry, May, Volume: 22, Issue:5
Synthesis of hydroxy- and amino-substituted benzohydroxamic acids: inhibition of ribonucleotide reductase and antitumor activity.
AID93700Inhibitory concentration of compound against 3'-processing of HIV-1 integrase in experiment 11997Journal of medicinal chemistry, Mar-14, Volume: 40, Issue:6
Depsides and depsidones as inhibitors of HIV-1 integrase: discovery of novel inhibitors through 3D database searching.
AID93707Inhibitory concentration of compound against strand transfer of HIV-1 integrase in experiment 21997Journal of medicinal chemistry, Mar-14, Volume: 40, Issue:6
Depsides and depsidones as inhibitors of HIV-1 integrase: discovery of novel inhibitors through 3D database searching.
AID91589Inhibitory concentration of compound against strand transfer of HIV- integrase1997Journal of medicinal chemistry, Mar-14, Volume: 40, Issue:6
Depsides and depsidones as inhibitors of HIV-1 integrase: discovery of novel inhibitors through 3D database searching.
AID93705Inhibitory concentration of compound against strand transfer of HIV-1 integrase in experiment 11997Journal of medicinal chemistry, Mar-14, Volume: 40, Issue:6
Depsides and depsidones as inhibitors of HIV-1 integrase: discovery of novel inhibitors through 3D database searching.
AID1124478Antitumor activity against mouse L1210 cells allografted in C6D2F1 mouse at 10 to 1000 mg/kg, ip for 8 days starting from day 1 of challenge relative to control1979Journal of medicinal chemistry, May, Volume: 22, Issue:5
Synthesis of hydroxy- and amino-substituted benzohydroxamic acids: inhibition of ribonucleotide reductase and antitumor activity.
AID1124482Antitumor activity against mouse L1210 cells allografted in C6D2F1 mouse at 139 mg/kg, ip bid at interval of 5 hrs between each dosing for 8 days starting from day 1 of challenge relative to control1979Journal of medicinal chemistry, May, Volume: 22, Issue:5
Synthesis of hydroxy- and amino-substituted benzohydroxamic acids: inhibition of ribonucleotide reductase and antitumor activity.
AID93702Inhibitory concentration of compound against 3'-processing of HIV-1 integrase in experiment 21997Journal of medicinal chemistry, Mar-14, Volume: 40, Issue:6
Depsides and depsidones as inhibitors of HIV-1 integrase: discovery of novel inhibitors through 3D database searching.
AID1124483Antitumor activity against mouse L1210 cells allografted in C6D2F1 mouse at 139 mg/kg, ip bid at interval of 7 hrs between each dosing for 8 days starting from day 1 of challenge relative to control1979Journal of medicinal chemistry, May, Volume: 22, Issue:5
Synthesis of hydroxy- and amino-substituted benzohydroxamic acids: inhibition of ribonucleotide reductase and antitumor activity.
AID1124492Antitumor activity against mouse L1210 cells allografted in C6D2F1 mouse at 400 mg/kg, ip for 8 days starting from day 1 of challenge relative to control1979Journal of medicinal chemistry, May, Volume: 22, Issue:5
Synthesis of hydroxy- and amino-substituted benzohydroxamic acids: inhibition of ribonucleotide reductase and antitumor activity.
AID1124481Antitumor activity against mouse L1210 cells allografted in C6D2F1 mouse at 139 mg/kg, ip bid at interval of 3 hrs between each dosing for 8 days starting from day 1 of challenge relative to control1979Journal of medicinal chemistry, May, Volume: 22, Issue:5
Synthesis of hydroxy- and amino-substituted benzohydroxamic acids: inhibition of ribonucleotide reductase and antitumor activity.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19905 (83.33)18.7374
1990's1 (16.67)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.35

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.35 (24.57)
Research Supply Index1.95 (2.92)
Research Growth Index4.29 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.35)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
digallic acid
digallic acid: structure given in first source		1.9910benzoate ester;
gallate ester
3-aminobenzamide
[no description available]		1.9610benzamides;
substituted aniline		EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor
3,4-dihydroxybenzohydroxamic acid
[no description available]		2.6630benzoic acids
hydroxyurea
[no description available]		2.6530one-carbon compound;
ureas		antimetabolite;
antimitotic;
antineoplastic agent;
DNA synthesis inhibitor;
EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor;
genotoxin;
immunomodulator;
radical scavenger;
teratogenic agent
methyl methanesulfonate
[no description available]		1.9610methanesulfonate esteralkylating agent;
apoptosis inducer;
carcinogenic agent;
genotoxin;
mutagen
cytarabine
[no description available]		1.9610beta-D-arabinoside;
monosaccharide derivative;
pyrimidine nucleoside		antimetabolite;
antineoplastic agent;
antiviral agent;
immunosuppressive agent
isoxazoles
Isoxazoles: Azoles with an OXYGEN and a NITROGEN next to each other at the 1,2 positions, in contrast to OXAZOLES that have nitrogens at the 1,3 positions.. isoxazole : A monocyclic heteroarene with a structure consisting of a 5-membered ring containing three carbon atoms and an oxygen and nitrogen atom adjacent to each other. It is the parent of the class of isoxazoles.. isoxazoles : Oxazoles in which the N and O atoms are adjacent.		1.9610isoxazoles;
mancude organic heteromonocyclic parent;
monocyclic heteroarene
benzohydroxamic acid
[no description available]		1.9510
psoromic acid
psoromic acid: structure in first source		1.9910carbonyl compound
1,4,5,8-naphthalenetetracarboxylic acid
1,4,5,8-naphthalenetetracarboxylic acid: structure given in first source		1.9910
ribavirin
Rebetron: Rebetron is tradename		1.96101-ribosyltriazole;
aromatic amide;
monocarboxylic acid amide;
primary carboxamide		anticoronaviral agent;
antiinfective agent;
antimetabolite;
antiviral agent;
EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor
physodic acid
physodic acid: lichen constituent		1.9910carbonyl compound
salicylhydroxamic acid
[no description available]		1.9510hydroxamic acid;
phenols		antibacterial drug;
EC 1.11.2.2 (myeloperoxidase) inhibitor;
EC 3.5.1.5 (urease) inhibitor;
trypanocidal drug
5,5'-methylenedisalicylic acid
5,5'-methylenedisalicylic acid: inhibits attachment of ribosomes to microsomal membranes; RN given refers to parent cpd; structure in first source & Merck Index, 9th ed, #5934		1.9910
atranorin
atranorin: RN given refers to parent cpd; structure given in first source		1.9910carbonyl compound
methyl fluorone black
methyl fluorone black: structure		1.9910
stictic acid
stictic acid: antioxidant from lichen, Usnea articulata; structure in first source		1.9910aromatic ether
diffractaic acid
difractaic acid: from Lichen, Usnea steineri; active against Gram-positive, multidrug-resistant bacteria; structure in first source		1.9910carbonyl compound
pannarin
pannarin: photoirradiation of above cpd leads to its decomposition which is reduced by oxygen. pannarin : A member of the class of depsidones that is 11H-dibenzo[b,e][1,4]dioxepine substituted by methyl groups at positions 1,6 and 9, chloro group at position 2, hydroxy group at position 3, formyl group at position 4, methoxy group at position 8 and an oxo group at position 11. It is a lichen metabolite isolated from several Psoroma species.		1.9910aldehyde;
aromatic ether;
depsidones;
organic heterotricyclic compound;
organochlorine compound;
phenols		antimicrobial agent;
antineoplastic agent;
apoptosis inducer;
lichen metabolite
acivicin
[no description available]		1.9610isoxazoles;
non-proteinogenic L-alpha-amino acid;
organochlorine compound		antileishmanial agent;
antimetabolite;
antimicrobial agent;
antineoplastic agent;
EC 2.3.2.2 (gamma-glutamyltransferase) inhibitor;
glutamine antagonist;
metabolite
tiazofurin
tiazofurin: RN given refers to (beta-D)-isomer; structure given in first source. tiazofurine : A C-glycosyl compound that is 1,3-thiazole-4-carboxamide in which the hydrogen at position 2 has been replaced by a beta-D-ribofuranosyl group. It is metabolised to thiazole-4-carboxamide adenine dinucleotide (TAD), a selective inhibitor of inosine monophosphate dehydrogenase (IMP dehydrogenase).		1.96101,3-thiazoles;
C-glycosyl compound;
monocarboxylic acid amide		antineoplastic agent;
EC 1.1.1.205 (IMP dehydrogenase) inhibitor;
prodrug
(+)-usnic acid
[no description available]		1.9910usnic acid
chlorogenic acid
caffeoylquinic acid: Antiviral Agent; structure in first source. chlorogenate : A monocarboxylic acid anion that is the conjugate base of chlorogenic acid; major species at pH 7.3.		1.9910cinnamate ester;
tannin		food component;
plant metabolite
mitolactol
Mitolactol: Alkylating antineoplastic toxic to bone marrow; used in breast cancer, also in combination with other drugs.		1.9610alcohol;
organobromine compound
fumarprotocetraric acid
fumarprotocetraric acid: RN given refers to (E)-isomer; structure given in first source		1.9910carbonyl compound
salazinic acid
salazinic acid: lichen metabolite; structure in first source		1.9910
4,5-di-O-caffeoylquinic acid
[no description available]		1.9910quinic acid
ribose
ribopyranose : The pyranose form of ribose.		1.9610D-ribose;
ribopyranose
pyrazofurin
pirazofurin : A C-glycosyl compound that is 4-hydroxy-1H-pyrazole-5-carboxamide in which the hydrogen at position 3 has been replaced by a beta-D-ribofuranosyl group.		1.9610C-glycosyl compound;
pyrazoles		antimetabolite;
antimicrobial agent;
antineoplastic agent;
EC 4.1.1.23 (orotidine-5'-phosphate decarboxylase) inhibitor
ConditionIndicatedRelationship StrengthStudiesTrials
Leukemia L 1210
[description not available]		01.9510
Experimental Hepatoma
[description not available]		02.6530
Granulocytic Leukemia
[description not available]		01.9610
Leukemia, Myeloid
Form of leukemia characterized by an uncontrolled proliferation of the myeloid lineage and their precursors (MYELOID PROGENITOR CELLS) in the bone marrow and other sites.		01.9610